Janus Henderson Group PLC Makes New $281,000 Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT)

Janus Henderson Group PLC acquired a new stake in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 46,900 shares of the company's stock, valued at approximately $281,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Graham Capital Management L.P. bought a new position in Adaptive Biotechnologies during the 4th quarter valued at $245,000. Deutsche Bank AG lifted its position in shares of Adaptive Biotechnologies by 397.6% during the fourth quarter. Deutsche Bank AG now owns 630,577 shares of the company's stock valued at $3,783,000 after purchasing an additional 503,842 shares in the last quarter. Driehaus Capital Management LLC lifted its position in shares of Adaptive Biotechnologies by 94.4% during the fourth quarter. Driehaus Capital Management LLC now owns 846,171 shares of the company's stock valued at $5,073,000 after purchasing an additional 410,877 shares in the last quarter. Cubist Systematic Strategies LLC boosted its holdings in Adaptive Biotechnologies by 5.3% during the fourth quarter. Cubist Systematic Strategies LLC now owns 315,098 shares of the company's stock worth $1,889,000 after purchasing an additional 15,817 shares during the last quarter. Finally, Brevan Howard Capital Management LP bought a new stake in Adaptive Biotechnologies in the 4th quarter worth about $150,000. 99.17% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Morgan Stanley boosted their target price on Adaptive Biotechnologies from $7.00 to $9.00 and gave the stock an "equal weight" rating in a research note on Monday, May 5th. Piper Sandler reissued an "overweight" rating and issued a $13.00 price objective (up previously from $11.00) on shares of Adaptive Biotechnologies in a research report on Tuesday, May 6th. The Goldman Sachs Group raised their target price on Adaptive Biotechnologies from $9.00 to $10.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Finally, Scotiabank lifted their target price on Adaptive Biotechnologies from $10.00 to $12.00 and gave the stock a "sector outperform" rating in a research note on Thursday, February 13th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, Adaptive Biotechnologies currently has a consensus rating of "Moderate Buy" and a consensus price target of $9.83.

Adaptive Biotechnologies Stock Performance

Shares of Adaptive Biotechnologies stock traded up $0.16 during midday trading on Thursday, reaching $9.31. 1,752,595 shares of the company's stock traded hands, compared to its average volume of 1,578,084. The stock has a 50 day moving average of $8.28 and a 200-day moving average of $7.42. Adaptive Biotechnologies Co. has a 12 month low of $2.99 and a 12 month high of $10.28. The company has a market cap of $1.41 billion, a PE ratio of -8.54 and a beta of 1.75.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.08. The company had revenue of $52.44 million for the quarter, compared to analysts' expectations of $42.13 million. Adaptive Biotechnologies had a negative return on equity of 64.65% and a negative net margin of 89.12%. The firm's revenue for the quarter was up 25.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.33) earnings per share. On average, equities analysts anticipate that Adaptive Biotechnologies Co. will post -0.92 earnings per share for the current fiscal year.

Insider Transactions at Adaptive Biotechnologies

In other news, insider Harlan S. Robins sold 68,412 shares of the company's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $7.35, for a total transaction of $502,828.20. Following the completion of the sale, the insider now owns 1,279,524 shares of the company's stock, valued at $9,404,501.40. This represents a 5.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Peter M. Neupert sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $7.05, for a total transaction of $70,500.00. Following the sale, the director now owns 224,690 shares in the company, valued at approximately $1,584,064.50. The trade was a 4.26% decrease in their position. The disclosure for this sale can be found here. Insiders sold 358,754 shares of company stock worth $2,584,806 over the last quarter. 6.40% of the stock is currently owned by insiders.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.